|
|
|
Volumn 247, Issue 4, 2000, Pages 31-33
|
|
Costs in the treatment of parkinsonism
|
|
Author keywords
Cost benefit analyses; Costs; Neuroprotection; Parkinson's disease
|
|
Indexed keywords
AMANTADINE;
BENSERAZIDE PLUS LEVODOPA;
BROMOCRIPTINE;
BROMOCRIPTINE MESILATE;
BUDIPINE;
CABERGOLINE;
CATECHOL METHYLTRANSFERASE INHIBITOR;
DOPAMINE RECEPTOR STIMULATING AGENT;
LEVODOPA;
PERGOLIDE;
ROPINIROLE;
SELEGILINE;
TRIHEXYPHENIDYL;
COST BENEFIT ANALYSIS;
DRUG COST;
HEALTH CARE COST;
HOSPITALIZATION;
HUMAN;
NEUROPROTECTION;
PARKINSON DISEASE;
PRIORITY JOURNAL;
QUALITY OF LIFE;
REVIEW;
ANTIPARKINSON AGENTS;
COST-BENEFIT ANALYSIS;
DRUG COSTS;
HUMANS;
PARKINSONIAN DISORDERS;
|
|
EID: 0033816348
PISSN: 09391517
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (18)
|
|
References (6)
|
